Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on Major Histocompatibility Complex Class I Gene Expression

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 1996 Feb 1

PMID 8808429

Citations 2

Authors

F Hirano

H Tanaka

Y Makino

K Okamoto

I Makino

Affiliations

Soon will be listed here.

Abstract

We investigated the effect of ursodeoxycholic acid on major histocompatibility complex class I gene expression in cultured human hepatoma cells. Ursodeoxycholic acid, which is now being used for the treatment of various autoimmune liver diseases, paradoxically increased the mRNA level of major histocompatibility complex class I. However, endogenous bile acids, for example, chenodeoxycholic acid, increased major histocompatibility complex class I mRNA expression more strongly compared with ursodeoxycholic acid. Concerning the interplay between ursodeoxycholic and chenodeoxycholic acids, these bile acids additively induced major histocompatibility complex class I mRNA expression. In contrast, when the total concentration of ursodeoxycholic and chenodeoxycholic acids was kept constant, the expression of major histocompatibility complex class I mRNA appeared to decrease in a dose-dependent manner with an increasing ratio of ursodeoxycholic acid. These findings indicate that the beneficial action of ursodeoxycholic acid may be related to this relative decrease in major histocompatibility complex class I gene expression.

Citing Articles

Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review.

Reardon J, Hussaini T, Alsahafi M, Marquez Azalgara V, Erb S, Partovi N J Clin Transl Hepatol. 2016; 4(3):192-205.

PMID: 27777888 PMC: 5075003. DOI: 10.14218/JCTH.2016.00023.

The management of primary sclerosing cholangitis.

Chapman R Curr Gastroenterol Rep. 2003; 5(1):9-17.

PMID: 12530943 DOI: 10.1007/s11894-003-0004-z.

References

Innes G, Nagafuchi Y, Fuller B, Hobbs K . Increased expression of major histocompatibility antigens in the liver as a result of cholestasis. Transplantation. 1988; 45(4):749-52. DOI: 10.1097/00007890-198804000-00017. View

Bouchard G, Yousef I, Tuchweber B . Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes. Liver. 1993; 13(4):193-202. DOI: 10.1111/j.1600-0676.1993.tb00630.x. View

Chretien Y, Poupon R, Gherardt M, Chazouilleres O, Labbe D, Myara A . Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut. 1989; 30(8):1110-5. PMC: 1434170. DOI: 10.1136/gut.30.8.1110. View

Poupon R, Eschwege E, Poupon R . Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol. 1990; 11(1):16-21. DOI: 10.1016/0168-8278(90)90265-s. View

Calmus Y, Gane P, Rouger P, Poupon R . Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990; 11(1):12-5. DOI: 10.1002/hep.1840110104. View

Ballardini G, Bianchi F, Mirakian R, FALLANI M, Pisi E, Bottazzo G . HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol. 1987; 70(1):35-46. PMC: 1542210. View

Heuman D, Pandak W, Hylemon P, VLAHCEVIC Z . Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology. 1991; 14(5):920-6. DOI: 10.1002/hep.1840140527. View

Sood A, Pereira D, Weissman S . Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. Proc Natl Acad Sci U S A. 1981; 78(1):616-20. PMC: 319105. DOI: 10.1073/pnas.78.1.616. View

Galle P, Theilmann L, Raedsch R, Otto G, Stiehl A . Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 1990; 12(3 Pt 1):486-91. DOI: 10.1002/hep.1840120307. View

10.

Hirano F, Tanaka H, Makino Y, Okamoto K, Inaba M, Miura T . Regulation of the major histocompatibility complex class I mRNA expression by bile acids in cultured human hepatoma cells. Biochem Biophys Res Commun. 1995; 208(3):935-42. DOI: 10.1006/bbrc.1995.1424. View

11.

Kakis G, Phillips M, Yousef I . The respective roles of membrane cholesterol and of sodium potassium adenosine triphosphatase in the pathogenesis of lithocholate-induced cholestasis. Lab Invest. 1980; 43(1):73-81. View

12.

Quist R, Lillienau J, Hofmann A, Barrett K . Activation of mast cells by bile acids. Gastroenterology. 1991; 101(2):446-56. DOI: 10.1016/0016-5085(91)90024-f. View

13.

Poupon R, Poupon R, Balkau B . Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994; 330(19):1342-7. DOI: 10.1056/NEJM199405123301903. View

14.

Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A . Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989; 97(5):1268-74. DOI: 10.1016/0016-5085(89)91698-3. View

15.

Miyazaki K, Nakayama F, Koga A . Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes. Dig Dis Sci. 1984; 29(12):1123-30. DOI: 10.1007/BF01317087. View

16.

Sherlock S . Primary biliary cirrhosis: clarifying the issues. Am J Med. 1994; 96(1A):27S-33S. View

17.

Lindor K, Burnes J . Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology. 1991; 101(1):250-3. DOI: 10.1016/0016-5085(91)90486-5. View

18.

Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K . Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol. 1991; 86(9):1194-9. View

19.

Batta A, Arora R, Salen G, Tint G, Eskreis D, Katz S . Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res. 1989; 30(12):1953-62. View

20.

Hirano F, Tanaka H, Makino I . Chenodeoxycholic acid-dependent induction of major histocompatibility complex class I mRNA expression in a human hepatoma cell line. Biochem Biophys Res Commun. 1993; 195(3):1408-14. DOI: 10.1006/bbrc.1993.2200. View